

AMENDMENT

Please amend the application without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

In the Claims

1-48. (Cancelled)

48. (Currently amended) A method of reducing T-cell activation by administering a Notch ligand comprising a DSL domain to a patient in need thereof, wherein the Notch ligand is Serrate, wherein the Notch ligand interacts with a Notch receptor, thereby reducing T-cell activation, and wherein the T-cell activation occurs with allergy or graft rejection or both allergy and graft rejection.

49. (Cancelled)

50. (Currently amended) A method of reducing T-cell activation by administering a Notch ligand comprising a DSL domain to a patient in need thereof, wherein the Notch ligand is Delta, wherein the Notch ligand interacts with a Notch receptor, thereby reducing T-cell activation, and wherein the T-cell activation occurs with allergy or graft rejection or both allergy and graft rejection.

51. (Cancelled)

52. (New) The method of claim 48, wherein the T-cell activation occurs with allergy.

53. (New) The method of claim 48, wherein the T-cell activation occurs with graft rejection.

54. (New) The method of claim 50, wherein the T-cell activation occurs with allergy.

55. (New) The method of claim 50, wherein the T-cell activation occurs with graft rejection.